Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov;27(11):1830–1842. doi: 10.1101/gr.222794.117

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Bhattacharyya et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Figure 7. — BRD4 inhibition leads to abrogation of pancreatic cancer growth in vitro and in vivo. (A) Pancreatic cancer cells were treated with varying doses of BRD4 inhibitor JQ1 and viability was assessed by MTS assay. (B) MYC expression was evaluated after 48 h of treatment with JQ1 in pancreatic cancer cells by qRT-PCR. (C) Athymic nude mice with established bilateral subcutaneous Pa04C xenografts were treated with either vehicle (n = 7 mice) or JQ1 (n = 8 mice) by daily i.p. injection. Treatment with JQ1 significantly inhibited tumor growth (P = 0.001). Mean ± SEM is plotted. (D) Treatment with JQ1 resulted in significantly decreased MYC mRNA expression as measured in excised tumors by qRT-PCR (P < 0.0001). Mean ± SEM is indicated by bars. (E) Ki67 immunohistochemistry and H&E stained sections from representative xenograft per treatment arm. A marked decrease in the proliferation marker Ki67 was observed in xenografts treated with JQ1.